



HIV/AIDS, Viral Hepatitis, STI and TB Prevention

FY2026 Operating Plan vs FY2027 President's Budget · Dollars in millions · FY2027 = President's Budget Request only — no enacted data available

FY2026 TOTAL \$1,384M One CDC program	NET REDUCTION -\$864M -62.4% vs FY2026	FY2027 — CDC \$300M VH/STI/TB grant only	FY2027 — AHA \$220M Ending HIV Epidemic program only
---	--	--	--

HOW THE PROGRAM IS RESTRUCTURED UNDER THE FY2027 PRESIDENT'S BUDGET



SUB-PROGRAM DETAIL

FY2026 Operating Plan · sub_agency: CDC · \$1,384.1M		FY2027 PB — CDC · \$300.0M	
Domestic HIV/AIDS Prevention and Research	\$1,013.7M	Consolidated hepatitis, STI & TB grant	\$300.0M
– Ending HIV/AIDS initiative	\$220.0M	(-\$47.3M vs VH, STI & TB combined FY2026)	
– School health – HIV	\$38.1M		
Viral hepatitis	\$46.0M		
STIs	\$164.3M		
Tuberculosis	\$137.0M		
Infectious Diseases and the Opioid Epidemic	\$23.0M		
		FY2027 PB — AHA · \$220.0M	
		Domestic HIV prevention & research	\$220.0M
		– Ending HIV epidemic initiative	\$220.0M
		All other Domestic HIV activities eliminated.	
		Only Ending the HIV Epidemic funded.	
		FY2027 PB — Eliminated	
		Infectious Diseases and the Opioid Epidemic	\$0 (was \$23.0M)
		\$0 (was ~\$793.7M)	
		All other Domestic HIV activities	~\$793.7M

KEY TAKEAWAYS

-62% Overall funding reduction from FY2026 OP to FY2027 PB	4→1 Four separate programs merged into one CDC grant	\$220M Domestic HIV funding retained (Ending HIV Epidemic initiative only)
--	--	--

SUMMARY

The FY2027 President's Budget proposes a fundamental restructuring of CDC's HIV, viral hepatitis, STI, and tuberculosis programs, reducing the combined total by \$864.1 million (62.4%) and splitting funding across two agencies for the first time. Domestic HIV Prevention and Research — which received \$1,013.7 million in FY2026 — would be cut to \$220.0 million and transferred to the Administration for a Healthy America (AHA), retaining only the Ending the HIV Epidemic initiative; all other Domestic HIV activities are eliminated. Viral hepatitis (\$46.0M), STIs (\$164.3M), and tuberculosis (\$137.0M) are consolidated into a single \$300.0 million CDC grant — a reduction of \$47.3 million from their combined FY2026 level. The Infectious Diseases and the Opioid Epidemic program (\$23.0M) is fully eliminated and is not included in the consolidated grant. If enacted, this would mark the first time domestic HIV prevention is funded outside of CDC, and would represent the largest single-year reduction to this program area in the dataset's FY2024–FY2027 coverage period.

Data sources: FY2026 CDC Operating Plan (cdc.gov/budget/fy2026/operating-plan.pdf) · FY2027 CDC Congressional Justification (cdc.gov/budget/fy2027/cj.pdf) · FY2027 Administration for a Healthy America Congressional Justification (hhs.gov/files/fy-2027-aha-cj.pdf)